Vizarsin 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0036 
Minor change in labelling or package leaflet not 
22/02/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0035 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
01/07/2022 
SmPC and PL 
To update section 4.5 of the SmPC to add a warning about 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
the increase in hypotension observed with concomitant use 
of sildenafil and sacubitril/valsartan. The Package leaflet is 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
assessment done under A 45/46 - Other variation 
updated accordingly. 
N/0034 
Minor change in labelling or package leaflet not 
06/01/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0033 
B.II.a.3.a.1 - Changes in the composition 
01/02/2021 
24/01/2022 
SmPC, 
(excipients) of the finished product - Changes in 
components of the flavouring or colouring system - 
Addition , deletion or replacement 
Labelling and 
PL 
IB/0032/G 
This was an application for a group of variations. 
06/11/2020 
24/01/2022 
SmPC, Annex 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IA/0031 
B.II.b.4.a - Change in the batch size (including batch 
27/02/2020 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
II/0029 
B.I.a.1.b - Change in the manufacturer of AS or of a 
12/09/2019 
n/a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
IA/0030 
B.III.2.b - Change to comply with Ph. Eur. or with a 
30/10/2018 
n/a 
national pharmacopoeia of a Member State - Change 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IB/0028 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
06/12/2017 
31/01/2019 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
N/0027 
Minor change in labelling or package leaflet not 
14/07/2017 
31/01/2019 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IB/0026/G 
This was an application for a group of variations. 
17/05/2016 
28/04/2017 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
N/0025 
Amendment of section 5 of the carton label text for 
01/03/2016 
28/04/2017 
Labelling 
the trilingual version in accordance with the 
assessment of EMEA/H/C/001076/IB/024. In 
addition, linguistic changes have also been made in 
section 5 of the trilingual carton label in order to 
adjust the translation fully in accordance with the 
approved English version for the following 
languages: BG, DE, FR, HU, IT and NL. And one 
additional linguistic correction has been made to the 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
German PI in section 5 of the blister label to revise 
the translation of the instructions for the separation 
of the unit-dose blister for a better description. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IB/0024 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/01/2016 
22/02/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IA/0023 
B.I.a.3.a - Change in batch size (including batch size 
02/12/2015 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IB/0021 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
15/10/2015 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IAIN/0022 
B.III.2.a.1 - Change of specification(s) of a former 
06/10/2015 
n/a 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
IA/0020 
A.7 - Administrative change - Deletion of 
06/10/2015 
n/a 
manufacturing sites 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0019/G 
This was an application for a group of variations. 
16/07/2014 
28/07/2015 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0018 
Renewal of the marketing authorisation. 
20/03/2014 
16/05/2014 
SmPC, Annex 
Based on the CHMP review of the available information and 
II, Labelling 
on the basis of a re-evaluation of the benefit risk balance, 
and PL 
the CHMP is of the opinion that the quality, safety and 
efficacy of Vizarsin continues to be adequately and 
sufficiently demonstrated and therefore considered that the 
benefit risk profile of Vizarsin continues to be favourable in 
the treatment of adult men with erectile dysfunction, which 
is the inability to achieve or maintain a penile erection 
sufficient for satisfactory sexual performance. In order for 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
IB/0017 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
26/11/2013 
20/12/2013 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Vizarsin to be effective, sexual stimulation is required. 
IB/0016/G 
This was an application for a group of variations. 
10/10/2013 
20/12/2013 
SmPC and PL 
1. Harmonisation of the PI in line with the Originator 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
product and update to the latest QRD template. The MAH 
also took the opportunity to make linguistic corrections in 
some of the languages. 
2. Update of Section 4.4 of the SmPC to revise the 
information on acute NAION based on new data coming 
from the clinical study A1481259 according to the 
Originator. The package leaflet was amended accordingly. 
N/0015 
Update of the list of local representatives contact 
17/07/2013 
20/12/2013 
Labelling and 
Update of the list of local representatives contact details 
details and addition of a local representative of the 
MAH for Croatia in the package leaflets. The MAH 
also corrected the pictograms for orodispersable 
tablets in the Labelling and in the Package Leaflet. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IB/0014/G 
This was an application for a group of variations. 
15/05/2013 
n/a 
PL 
and addition of a local representative of the MAH for 
Croatia in the package leaflets. The MAH also corrected the 
pictograms for orodispersable tablets in the Labelling and in 
the Package Leaflet. 
Page 6/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the currently approved batch 
size 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
14/03/2013 
20/12/2013 
SmPC, Annex 
Implementation of changes approved in the reference 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II and PL 
product - update of section 4.8 to add ‘Penile haemorrhage, 
Haematospermia, and Haematuria’ with an uncommon 
frequency and deletion of the footnote referring to ear 
disorders as requested by CHMP. The Package Leaflet was 
updated accordingly. The MAH also took the opportunity to 
update the list of local representatives for PL, PT and ES 
and to update Annex II according to the latest QRD 
template. 
IB/0012 
C.I.z - Changes (Safety/Efficacy) of Human and 
18/12/2012 
20/12/2013 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
X/0006 
Annex I_1.(a) Replacement of a chemical AS by diff. 
15/03/2012 
15/05/2012 
SmPC, 
See Assessment Report EMEA/H/C/001076/X/06 
salt/ester complex/derivative, with the same 
therapeutic moiety 
Annex I_2.(d) Change or addition of a new 
pharmaceutical form 
Labelling and 
PL 
N/0010 
Update of the Spanish local representative's contact 
28/11/2011 
15/03/2012 
PL 
Update of the Spanish local representative's contact details. 
details. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
Page 7/10 
 
 
 
 
 
 
 
 
 
 
 
IB/0009 
B.I.a.2.e - Changes in the manufacturing process of 
22/11/2011 
n/a 
the AS - Minor change to the restricted part of an 
ASMF 
IA/0008/G 
This was an application for a group of variations. 
27/10/2011 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished product - Minor change in the 
manufacturing process of an immediate release solid 
oral dosage form or oral solutions 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
IB/0007 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
25/08/2011 
n/a 
SmPC and PL 
- to extend the shelf life of the finished product from 24 to 
life of the finished product - As packaged for sale 
(supported by real time data) 
36 months 
- the MAH took the opportunity to correct editorial changes 
to the product information in Czech, Finnish and French 
IA/0005 
B.II.b.3.a - Change in the manufacturing process of 
28/01/2011 
n/a 
the finished product - Minor change in the 
manufacturing process of an immediate release solid 
oral dosage form or oral solutions 
IA/0004 
B.I.a.1.a - Change in the manufacturer of AS or of a 
15/12/2010 
n/a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0003 
Update of section 4.8 of the Summary of Product 
23/08/2010 
n/a 
SmPC and PL 
Characteristics to include severe cutaneous adverse 
drug reactions, i.e. Stevens Johnson syndrome and 
Toxic epidermal necrolysis. The Package Leaflet is 
amended accordingly. In addition, the web address 
of the EMA has been updated in Section 10 of the 
SmPC and in the PL. 
These changes were made to bring Vizarsin's product 
information in line with the reference medicinal 
product Viagra. 
Furthermore the MAH has updated the contact 
details of the local representatives in Spain, Latvia, 
Lithuania, Spain, Austria, Poland and the United 
Kingdom. In addition minor linguistic changes were 
introduced in the Latvian SmPC to align with the 
originator.  
In addition the MAH took this opportunity to make 
minor linguistic changes to the Danish and 
Norwegian annexes. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IA/0002 
IA_09_Deletion of manufacturing site 
23/11/2009 
n/a 
IA/0001 
IA_07_a_Replacement/add. of manufacturing site: 
10/11/2009 
n/a 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Secondary packaging site 
Page 10/10 
 
 
 
 
 
 
 
